Drugs Made in America Acquisition (DMAAU) Stock Price, News & Analysis

Company Overview

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.

Key Stats

• Today's Range: $10.60 to $10.60
• 50-Day Range: $10.29 to $10.60
• 52-Week Range: $10.00 to $10.82
• Volume: 76 shs
• Average Volume: 39,092 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DMAAU Stock Analysis - Frequently Asked Questions

How have DMAAU shares performed this year?

Drugs Made in America Acquisition's stock was trading at $10.00 at the beginning of 2025. Since then, DMAAU shares have increased by 6.0% and is now trading at $10.60.

When did Drugs Made in America Acquisition IPO?

Drugs Made in America Acquisition (DMAAU) raised $200 million in an initial public offering on Tuesday, January 28th 2025. The company issued 20,000,000 shares at a price of $10.00 per share. Clear Street served as the underwriter for the IPO.

When did Drugs Made in America Acquisition's lock-up period expire?

Drugs Made in America Acquisition's lock-up period expired on Monday, July 28th. Drugs Made in America Acquisition had issued 20,000,000 shares in its initial public offering on January 28th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

How do I buy shares of Drugs Made in America Acquisition?

Shares of DMAAU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:DMAAU
• CIK: 2028614
• Web: N/A
• Phone: (954) 870-3104
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A